My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every time.
Start Research-backed Investing ...in less than a minute.
1. Is Aarey Drugs & Pharmaceuticals Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Aarey Drugs & Pharmaceuticals Ltd is a below average quality company.
2. Is Aarey Drugs & Pharmaceuticals Ltd undervalued or overvalued?
The key valuation ratios of Aarey Drugs & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Aarey Drugs & Pharmaceuticals Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Aarey Drugs & Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | 3.2% | 4.3% | 4.8% | 5.1% | 15.3% | 10.2% | 8.7% | 6.6% | 7.2% | 6.5% | - | ||
| Value Creation Index ⓘ | -0.8 | -0.7 | -0.7 | -0.6 | 0.1 | -0.3 | -0.4 | -0.5 | -0.5 | -0.5 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 172 | 200 | 213 | 246 | 396 | 349 | 355 | 300 | 348 | 493 | 376 | ||
| YoY Gr. Rt. % | - | 15.9% | 6.9% | 15.3% | 60.9% | -12% | 1.7% | -15.4% | 16.1% | 41.4% | - | ||
| Adj EPS ⓘ | 0.4 | 0.6 | 0.6 | 0.8 | 3 | 2.6 | 2.8 | 2.5 | 2.8 | 2.6 | 1.1 | ||
| YoY Gr. Rt. % | - | 53.9% | 5% | 20.6% | 297.4% | -15.6% | 9.4% | -11.1% | 12.1% | -7.6% | - | ||
| BVPS (₹) ⓘ | 19.9 | 20.5 | 21 | 21.8 | 26.6 | 33.3 | 36 | 38.5 | 41.3 | 43.9 | 46.1 | ||
| Adj Net Profit ⓘ | 0.7 | 1 | 1.1 | 1.3 | 5.5 | 6 | 6.5 | 5.8 | 6.5 | 6.5 | 3 | ||
| Cash Flow from Ops. ⓘ | 3.4 | -0.4 | 3.3 | 5.7 | 0.6 | -20.4 | 0.7 | 2.9 | 5.5 | -4.5 | - | ||
| Debt/CF from Ops. ⓘ | 1.4 | -13.6 | 3.4 | 2.6 | 16.6 | -0.2 | 23.5 | 6.3 | 3.3 | -3.2 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 12.4% | 4.5% | 11.6% | 41.4% | ||||||||
| Adj EPS ⓘ | 23.3% | -3.2% | -2.7% | -7.6% | ||||||||
| BVPS ⓘ | 9.2 | 10.5 | 6.8 | 6.2 | ||||||||
| Share Price | 4.7% | -14.6% | 22.6% | -40.8% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | 2 | 3 | 3 | 3.5 | 12.7 | 9.2 | 7.8 | 6.5 | 6.8 | 6.1 | 2.3 | |
| Op. Profit Mgn % ⓘ | 1.2 | 0.7 | 0.6 | 0.4 | 2.4 | 2.2 | 2.2 | 1.1 | 1.3 | 2.3 | 1.9 | |
| Net Profit Mgn % ⓘ | 0.4 | 0.5 | 0.5 | 0.5 | 1.4 | 1.7 | 1.8 | 1.9 | 1.9 | 1.3 | 0.7 | |
| Debt to Equity ⓘ | 0.2 | 0.2 | 0.3 | 0.4 | 0.2 | 0 | 0.2 | 0.2 | 0.2 | 0.1 | - | |
| Working Cap Days ⓘ | 190 | 182 | 179 | 166 | 112 | 148 | 147 | 191 | 209 | 166 | 0 | |
| Cash Conv. Cycle ⓘ | 86 | 72 | 7 | 3 | 6 | 24 | 63 | 74 | 54 | 38 | 0 | |
Sales growth is growing at healthy rate in last 3 years 11.57%
Return on Equity has declined versus last 3 years average to 2.30%
Net Profit has been subdued in last 3 years -2.70%
Sales growth is not so good in last 4 quarters at -27.76%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 1.1 | - |
| TTM Sales (₹ Cr.) | 376 | - |
| BVPS (₹.) ⓘ | 46.1 | - |
| Reserves (₹ Cr.) ⓘ | 92 | - |
| P/BV ⓘ | 0.52 | - |
| PE ⓘ | 22.95 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 21.90 / 51.00 |
| All Time Low / High (₹) | 0.50 / 143.95 |
| Market Cap (₹ Cr.) | 61 |
| Equity (₹ Cr.) | 25.4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 45.4 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Aarey Drugs & Pharmaceuticals Ltd. was established in 1990. The company is engaged in the manufacturing of drugs and intermediates such as metronidazole, metronidazole benzoate, methyl, and nitro imidazole. The company is based in Thane, India.
The company also export its products to various other countries like Germany, Sri Lanka, Pakistan, Nepal and a number of African countries and is looking to establish its trade relations in other parts of the world as well.
Product range of the company includes: API/Intermediate
Drug deliveryPharmaceuticals / Therapeutics
Therapeutic targets of the company's products are:
Recent development
Aarey Drugs & Pharmaceuticals has recently informed that Atul A Zatakia has resigned from the Company as a Director with effect from March 01, 2009.
Download APP
